

Special Issue

New Insights on Management of Acute Lymphoblastic Leukemia in the Contemporary Era

Message from the Guest Editor

Acute lymphoblastic leukemia (ALL) is commonly seen in children and has excellent outcomes. In adults, it's more challenging to treat. In the last decade, we have seen improvement in the outcomes of adult with ALL by incorporating newer antibody constructs, including antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell (CAR T-cell) therapies. We have seen significant improvements in the outcome of Philadelphia chromosome positive (Ph+) B-cell ALL with the incorporation of BCR-ABL1 tyrosine kinase inhibitor (TKI) combinations. Patients are now able to achieve better responses and improvement in long-term outcome. There is also advancement in our ability to assess response to therapy with the use of extremely sensitive measurable residual disease assays including clonoSEQ and next-generation sequencing (NGS), which have helped treatments. While the outcome of patients with B-cell ALL has improved, there is still challenges in T-cell ALL. In this issue, we will highlight the current status of ALL management.

Guest Editor

Dr. Talha Badar

Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/206563

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)